Amgen vs IBM: Founders, CEOs and History

Company facts

Founders

CEOs and their tenures

Timeline: Amgen and IBM side by side

1. 1911IBM

   Computing-Tabulating-Recording Company Founded

   Charles Ranlett Flint merged the Tabulating Machine Company, International Time Recording Company, Computing Scale Company, and Bundy Manufacturing Company to form CTR - the company that would become IBM.

2. 1924IBM

   Renamed to International Business Machines

   Under Thomas J. Watson Sr. CTR was renamed International Business Machines Corporation (IBM), reflecting the company's growing international presence and ambition beyond tabulating machines.

3. 1952IBM

   IBM 701 - First Commercial Computer

   IBM launched the 701, its first commercially available electronic computer, marking the company's decisive entry into the electronic computing era and beginning its dominance of the mainframe market.

4. 1964IBM

   System/360 Launch

   IBM launched the System/360, a compatible family of computers spanning all price points. The $5 billion investment was the largest privately funded project at the time and established the mainframe industry standard for decades.

5. 1980Amgen

   Applied Molecular Genetics is incorporated

   Applied Molecular Genetics (AMGen) was incorporated on April 8, 1980 in Thousand Oaks, California, as the idea of venture capitalist William K. Bowes Jr. and a group of scientific collaborators.

6. 1981IBM

   IBM Personal Computer Launch

   IBM introduced the IBM PC, which standardized personal computing architecture and created the PC industry. The open architecture decision inadvertently created the Wintel duopoly that would ultimately commoditize IBM's own PC business.

7. 1983Amgen

   Nasdaq listing and the erythropoietin clone

   Amgen completed its initial public offering on June 17, 1983, raising nearly US$40 million under chief financial officer Gordon Binder, and formally shortened its name to Amgen.

8. 1984Amgen

   Kirin-Amgen joint venture formed

   Amgen and Kirin Brewery Company of Japan formed Kirin-Amgen in 1984 as a joint venture for the worldwide commercialization of erythropoietin.

9. 1985Amgen

   G-CSF cloned, leading to Neupogen

   While Fu-Kuen Lin's team worked on erythropoietin, researcher Larry Souza and his group cloned and expressed human granulocyte colony-stimulating factor in 1985.

10. 1989Amgen

    FDA approves Epogen

    The FDA approved Epogen (epoetin alfa) on June 1, 1989 for anemia in patients with chronic kidney failure on dialysis. It was the first commercial recombinant human erythropoietin. Epogen's U.S.

11. 1991Amgen

    Neupogen approved, giving Amgen a second franchise

    The FDA approved Neupogen (filgrastim) in February 1991. By stimulating white blood cell production it reduced the risk of infection in cancer patients with chemotherapy-induced neutropenia.

12. 1991Amgen

    Amgen wins the erythropoietin patent fight

    On March 6, 1991 the U.S. Court of Appeals for the Federal Circuit upheld the Kirin-Amgen erythropoietin patent and ruled against Genetics Institute in Amgen v. Chugai Pharmaceutical and Genetics Institute.

13. 1993IBM

    Lou Gerstner Arrives - Turnaround Begins

    Louis V. Gerstner Jr. Became CEO as IBM posted $8 billion in losses. His decision to keep IBM intact rather than break it up, and to pivot toward services, saved the company and redefined its business model for the next two decades.

14. 1997IBM

    Deep Blue Defeats Kasparov

    IBM's Deep Blue supercomputer defeated world chess champion Garry Kasparov, becoming the first computer to beat a reigning world champion in a full match and establishing IBM's brand in artificial intelligence.

15. 2001Amgen

    FDA approves Aranesp, the longer-acting EPO

    Aranesp (darbepoetin alfa), an erythropoietin analogue with modified glycosylation and a longer half-life, was approved in 2001. Less frequent dosing than Epogen improved convenience and gave Amgen a newer, higher-priced product to migrate patients toward.

16. 2002Amgen

    US$16 billion Immunex acquisition brings Enbrel in-house

    Amgen completed its acquisition of Immunex Corporation on July 16, 2002, the largest biotechnology deal to that point at about US$16 billion in stock and cash.

17. 2010Amgen

    Prolia and XGEVA create the bone health franchise

    The FDA approved Prolia (denosumab) for postmenopausal osteoporosis in June 2010 and XGEVA, the same molecule at a higher dose, for prevention of skeletal-related events in cancer patients in November 2010.

18. 2019Amgen

    US$13.4 billion purchase of Otezla from Celgene

    Amgen agreed in August 2019 to buy worldwide rights to Otezla (apremilast) from Celgene for US$13.4 billion in cash, or about US$11.2 billion net of the present value of US$2.2 billion of anticipated future cash tax benefits, and closed on November 21, 2019.

19. 2019IBM

    Red Hat Acquisition Closes

    IBM completed the $34 billion acquisition of Red Hat, the largest software acquisition in history at the time. The deal anchored IBM's hybrid cloud strategy and provided the OpenShift platform as the foundation for enterprise Kubernetes.

20. 2020Amgen

    Amgen joins the Dow Jones Industrial Average

    Amgen replaced Pfizer in the Dow Jones Industrial Average on August 31, 2020, becoming one of the thirty components in the index. Inclusion recognized the scale Amgen had reached and added passive demand from Dow-tracking funds.

21. 2021IBM

    Kyndryl Spinoff

    IBM spun off its managed infrastructure services business as Kyndryl Holdings, removing approximately $19 billion in low-margin revenue to focus the remaining company on higher-margin software and consulting.

22. 2023Amgen

    US$27.8 billion Horizon Therapeutics acquisition closes

    Amgen completed the acquisition of Horizon Therapeutics plc on October 6, 2023 for US$116.50 per share in cash, an equity value of about US$27.8 billion, after settling FTC litigation with a behavioral consent decree.

23. 2023IBM

    Watsonx Platform Launch

    IBM launched watsonx, its enterprise AI and data platform combining foundation models (Granite), data management (watsonx.data), and AI governance (watsonx.governance). The platform represents IBM's AI strategy for the generative AI era.

24. 2024Amgen

    Imdelltra becomes the first T-cell engager for small cell lung cancer

    The FDA granted accelerated approval to tarlatamab, sold as Imdelltra, on May 16, 2024 for extensive stage small cell lung cancer that has progressed on or after platinum-based chemotherapy.

25. 2025Amgen

    VESALIUS-CV extends the Repatha case to primary prevention

    In November 2025 Amgen reported Phase 3 VESALIUS-CV results in more than 12,000 patients with atherosclerosis or diabetes but no prior heart attack or stroke.

26. 2026Amgen

    Medicare price setting reaches Enbrel and Otezla

    Enbrel's negotiated Medicare price under the Inflation Reduction Act took effect on January 1, 2026, after it was named in the first round of ten drugs selected for negotiation.

27. 2026IBM

    Confluent Acquisition Closes

    IBM completed its roughly $11 billion acquisition of Confluent, adding real-time data streaming used by more than 6,500 enterprises to its AI and hybrid cloud software.

Acquisitions

Questions about Amgen vs IBM